Does Doxepin Show Up on a Drug Test? Employer Guide

Quick answer: Doxepin does not show up on standard 5-panel or 10-panel urine drug tests, because those panels do not screen for tricyclic antidepressants. It will appear on panels that include a TCA test, typically at a 1,000 ng/mL cutoff, usually for about two to four days after the last dose.

• Doxepin is a tricyclic antidepressant (TCA); the federal five-drug panel does not include TCAs.
• Only panels with a TCA line detect it; the common screening cutoff is 1,000 ng/mL.
• A TCA-positive screen is presumptive; confirm with lab testing and a medical review before acting.

What doxepin is and why it matters to testing programs

Doxepin is a prescription tricyclic medication. According to the National Library of Medicine's MedlinePlus, it is used to treat depression and anxiety, and low-dose forms are prescribed for insomnia. Because it is a legitimate medication taken by many employees, clients and probationers, programs need a clear policy on how it is handled.

Which drug test panels detect doxepin?

The HHS-regulated panel used for federal and DOT testing covers marijuana, cocaine, opiates, amphetamines and phencyclidine. The Department of Transportation's Office of Drug and Alcohol Policy and Compliance (ODAPC) governs that list for regulated employers, and tricyclic antidepressants are not on it. Common non-regulated 5- and 10-panel cups follow the same pattern. A TCA line appears mainly on extended panels (for example 12-panel and above) or on dedicated TCA strips.

Detection window and cutoff

Detection depends on dose, duration of use, metabolism, kidney function and urine concentration. Doxepin has a half-life of roughly 15 hours, and its active metabolite nordoxepin lasts longer, so a urine TCA screen is generally positive for a few days after the last dose. Heavier or chronic use may extend that. Low-dose insomnia prescriptions may fall below a 1,000 ng/mL screening cutoff, so a negative TCA result does not prove the person is not taking doxepin.

False positives and cross-reactivity

Immunoassay screens react to a drug's chemical structure, not its identity. Other tricyclic-like compounds, such as amitriptyline, nortriptyline and cyclobenzaprine (a muscle relaxant), can also trigger a TCA positive. Some immunoassays have also reported cross-reactivity between certain psychiatric medications and unrelated drug classes. Manufacturer package inserts list known cross-reactants, so review them for each device. Any non-negative screen should be treated as presumptive until confirmed.

How to read and handle a TCA result

1. Confirm the device's analyte list and cutoff before collection, so you know a TCA line exists.
2. Read the result within the time window in the instructions; do not interpret after the stated read time.
3. Treat any line-absent result in the TCA window as non-negative (a line present means negative on most cup designs).
4. Send non-negative specimens for laboratory confirmation.
5. Route confirmed positives to a medical review process, where the donor can document a prescription.

Choosing a device

Programs that need TCA screening can review multi-panel drug test cups and compare analyte lists and cutoffs. Verify each device's FDA clearance and CLIA-waiver status in its documentation before use in a clinical or point-of-care setting. If you are unsure which panel fits your policy, contact the American Screening Corp team.

Checklist for clinics, courts, employers and staffing firms

• Decide whether TCAs are in scope for your policy; most pre-employment programs do not need them.
• Match the panel to the policy, and do not add analytes that you will not act on.
• Document the cutoff (ng/mL) for every analyte on the device.
• Require lab confirmation for any non-negative screen.
• Use a medical review step for prescription disclosures, and keep that information confidential.
• Train collectors on read times and chain-of-custody steps.
• Ensure that DOT-regulated testing uses only the federal panel and procedures.
• Review the policy with qualified counsel to address disability and privacy rules.

Policy considerations

Prescription antidepressants are lawful medications. Acting on a TCA result without confirmation and medical review can create legal and fairness risks. Addiction-treatment and probation programs often include TCAs for clinical reasons, such as monitoring medication adherence or detecting misuse, while employers usually do not. Write down why the analyte is on the panel and what happens after a positive.

FAQ

Does doxepin show up on a standard 10-panel drug test?

Usually not. Standard 10-panel cups focus on drugs such as marijuana, cocaine, opiates, amphetamines, benzodiazepines and barbiturates. Doxepin appears only if the panel includes a TCA line.

Will doxepin cause a false positive on a DOT drug test?

DOT tests do not screen for tricyclics, and doxepin is not a regulated analyte. Any non-negative DOT result goes through certified laboratory confirmation and medical review officer verification.

How long does doxepin stay in urine?

Generally a few days after the last dose, around two to four days for many users. Dose, duration, metabolism and hydration change this, so treat it as an estimate.

What should we do if a TCA screen is positive?

Treat it as presumptive. Send the specimen for lab confirmation, then use a medical review process so the donor can document a valid prescription before any decision.

Sources

• MedlinePlus (NLM): Doxepin
• U.S. Department of Transportation: Office of Drug and Alcohol Policy and Compliance
• SAMHSA: Workplace Drug Testing Resources

Employers screening candidates beyond drug testing may also consider employment background checks from Reveal Background.

This article is general information, not legal or medical advice.